Shire’s Adynovate Receives Two New FDA Approvals for Treatment of Hemophilia A
Note: The following is edited from a press release from Shire. Read the full press release in it’s entirety here.
Shire plc recently announced that the U.S. Food and Drug Administration (FDA) has approved Adynovate, an extended circulating half-life recombinant Factor VIII treatment for hemophilia A, in pediatric patients under 12 years of age. The FDA also approved Adynovate for use in surgical settings for both adult and pediatric patients.
Assisting and Advocating for the Bleeding Disorders Community